Full-Life Technologies, a global company specializing in radiotherapeutics, has successfully secured a US$150 million financing package to advance its innovative cancer treatments. The funding, which includes approximately US$110 million in Series D equity and US$40 million in debt, was led by prominent healthcare investor Vivo Capital. This significant capital injection will fuel the clinical development of its drug pipeline and establish in-house manufacturing capabilities, marking a pivotal step in the company's growth.
Strategic Allocation of New Capital
The proceeds are earmarked for advancing the company's leading clinical-stage assets, which have emerged from its proprietary UniRDC™ discovery platform. Key programs include the potential best-in-class [225Ac]-FL-020 for treating prostate cancer and the potential first-in-class [225Ac]-FL-261 for various solid tumor indications. Full-Life aims to have three distinct clinical-stage programs underway by the end of 2026, solidifying its position in the radiopharmaceutical landscape.
A substantial portion of the funding will also facilitate the launch of GMP-grade Actinium-225 (225Ac) manufacturing at its state-of-the-art facility in Belgium. By gaining complete control over its isotope supply and production, Full-Life establishes a crucial strategic advantage in the competitive field. This vertical integration is designed to accelerate the rapid progression of its radiotherapeutics through clinical trials and towards potential commercialization without external supply constraints.
Investor Confidence and Company Vision
The financing round saw participation from strategic partner SK Biopharmaceuticals and other renowned shareholders, signaling strong market confidence in Full-Life's direction. Hao Dong, Managing Director at lead investor Vivo Capital, praised the company's ability to translate scientific vision into tangible clinical and operational achievements on a global scale. He noted that the investment reflects a firm belief in Full-Life's evolution from a platform innovator into a fully integrated radiopharmaceutical leader.
Full-Life's leadership views this capital infusion as a validation of the significant value created since its founding. Julie Wu, President and Chief Financial Officer, stated that the financing acknowledges the company's successful transition from a platform builder to a clinical-stage entity. The new funds are expected to accelerate the company’s move toward late-stage development and ensure its Belgium facility becomes fully operational to support global commercial supply needs.
A Growing Force in Radiopharmaceuticals
This latest round brings Full-Life's total funding to nearly US$350 million since its inception in 2021, underscoring its rapid ascent in the life sciences sector. The company's mission is to manage the entire value chain for radiopharmaceuticals, from research and development to production and commercialization. This comprehensive approach aims to overcome fundamental challenges in the field and deliver powerful new treatments to cancer patients worldwide.
Lead investor Vivo Capital, a global healthcare investment firm founded in 1996, brings substantial expertise and resources to the partnership. Managing over $7.0 billion, Vivo Capital focuses exclusively on sectors like biotechnology and pharmaceuticals, employing an "Ecosystem Strategy" that provides strategic support beyond capital. Their involvement underscores the high potential they see in Full-Life's technology and integrated business model to impact the oncology market significantly.
In conclusion, the US$150 million financing round marks a transformative moment for Full-Life Technologies, equipping it with the resources to accelerate its mission. By strategically investing in both its advanced clinical pipeline and its manufacturing independence, the company is strongly positioned to become a key player in the radiotherapeutics industry. This dual focus on innovation and supply chain control paves the way for delivering next-generation cancer therapies to patients globally.